Advances in the treatment of hairy-cell leukaemia

Lancet Oncology

Volumn 4, Issue 2, 2003, Pages 86-94

  Mey, Ulrich ^a   Strehl, John ^a   Gorschlüter, Marcus ^a   Ziske, Carsten ^a   Glasmacher, Axel ^a   Pralle, Hans ^b   Schmidt Wolf, Ingo ^a  

^a UNIVERSITY OF BONN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BASILIXIMAB; CLADRIBINE; FLUDARABINE; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD22; PARACETAMOL; PENTOSTATIN; PSEUDOMONAS EXOTOXIN; PURINE DERIVATIVE; RITUXIMAB; UNCLASSIFIED DRUG;

ALGORITHM; AMNESIA; ANOREXIA; B LYMPHOCYTE; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG RESPONSE; DRY SKIN; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; HAIRY CELL LEUKEMIA; HUMAN; INFECTION; LEUKEMIA REMISSION; LYMPHOPROLIFERATIVE DISEASE; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; SPLENECTOMY; SPLENOMEGALY; TACHYPHYLAXIS;

EID: 0037320558     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)00980-X     Document Type: Review

References (81)

1. Bouroncle BA, Wiseman BK, Doan CA, Leukemic reticuloendotheliosis. Blood 1958; 13: 609-30.
2. Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles Country. Cancer Res 1990; 50: 3605-09.
3. Saven A, Piro LD. Treatment of hairy cell leukemia. Blood 1992; 9: 1111-20.
4. Van Norman AS, Nagorney DM, Martin JK, et al. Splenectomy for hairy cell leukemia: a clinical review of 63 patients. Cancer 1986;57: 644-48.
5. Jansen J, Hermans J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer 1981; 47: 2066-76.
6. Quesada JR, Rueben J, Manning JT, et al. Alpha interferon dor induction of remission in hairy-cell leukemia. N Engl J Med 1984: 310- 15-18.
7. Berman E, Heller G, Kempin S, et al. Incident of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 1990; 75:839-45.
8. Golomb HM, Ratain MJ, Fefer A, et al. Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia. J Natl Cancer Inst 1988; 80: 369-73.
9. Quesada JR, Hersh EM, Manning J, et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 1986; 68: 493-97.
10. Ratain MJ, Golomb HM, Vardiman JW, et al. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. J Clin Oncol 1988; 6: 1714-21.
11. Smith JW 2nd, Longo DL, Urba WJ, et al. Prolonged, continous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. Blood 1991; 78: 1664-71.
12. Federico M, Frassoldati A, Lamparelli T, et al. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia: final report from the Italian Cooperative Group for HCL. Ann Oncol 1994; 5: 725-31.
13. Smalley RV, Connors J, Tuttle RL, et al. Splenectomy vs. alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia. Am J Hematol 1992; 41: 13-18.
14. Damasio EE, Clavio M, Masoudi B, et al. Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis. Eur J Haematol 2000; 64: 47-52.
15. Gollard R, Lee TC, Piro LD, Saven A. The optimal management of hairy cell leukaemia. Drugs 1995; 49: 921-31.
16. Troussard X, Flandrin G. Hairy cell leukemia: an update on a cohort of 93 patients treated in a single institution. Effects of interferon in patients relapsing after splenectomy and in patients with or without maintenance treatment. Leuk Lymphoma 1994; 14: 99-105.
17. Bourantas KL, Hatzimichael EC, Makis AC, et al. Prolonged interferon-alpha-2b treatment of hairy cell leukemia patients. Eur J Haematol 2000; 64: 350-51.
18. Habermann TM, Andersen JW, Cassileth PA, et al. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol 1992; 80: 466-71.
19. Spiers AS, Parekh SJ, Bishop MB. Hairy-cell leukemia: induction of complete remission with pentostatin (2′-deoxycoformycin). J Clin Oncol 1984; 2: 1336-42.
20. Cassileth PA, Cheuvart B, Spiers AS, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 1991; 9: 243-46.
21. Catovsky D, Matutes E, Talavera JG, et al. Long term results with 2′ deoxycoformycin in hairy cell leukemia. Leuk Lymphoma 1994; 14: 109-13.
22. Golomb HM, Dodge R, Mick R, et al. Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515. Leukemia 1994; 8: 2037-40.
23. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995; 13: 974-82.
24. Ho AD, Thaler J, Mandelli F, et al. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1989; 7: 1533-38.
25. Johnston JB, Eisenhauer E, Corbett WE, et al. Efficacy of 2′-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst 1988; 80: 765-69.
26. Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 1994; 84: 4061-63.
27. Blick M, Lepe-Zuniga JL, Doig R, Quesada JR. Durable complete remissions after 2′-deoxycoformycin treatment in patients with hairy cell leukemia resistant to interferon alpha. Am J Hematol 1990; 33: 205-09.
28. Annino L, Ferrari A, Giona F, et al. Deoxycoformycin induces long-lasting remissions in hairy cell leukemia: clinical and biological results of two different regimens. Leuk Lymphoma 1994; 14 (suppl 1): 115-19.
29. Rafel M, Cervantes F, Beltran JM, et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 2000; 88: 352-57.
30. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000; 96: 2981-86.
31. Martin A, Nerenstone S, Urba WJ, et al. Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study. J Clin Oncol 1990; 8: 721-30.
32. Ribeiro P, Bouaffia F, Peaud PY, et al. Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 1999; 85: 65-71.
33. Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989; 7: 168-72.
34. Kraut EH, Neff JC, Bouroncle BA, et al. Immunosuppressive effects of pentostatin. J Clin Oncol 1990; 8: 848-55.
35. Margolis J, Grever MR. Pentostatin (Nipent): a review of potential toxicity and its management. Semin Oncol 2000; 27 (suppl 5): 9-14.
36. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. BCSH Blood Transfusion Task Force. Transfus Med 1996; 6: 261-71.
37. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117-21.
38. Saven A, Piro LD. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia. Cancer Invest 1993; 11: 559-64.
39. Piro LD, Ellison DJ, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994; 14 (suppl 1): 121-25.
40. Jehn U, Bartl R, Dietzfelbinger H, et al Long-term outcome of hairy cell leukemia treated with 2′-chlorodeoxyadenosine. Ann Hematol 1999; 78: 139-44.
41. Lauria F, Bocchia M, Marotta G, et al. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 1999; 84: 22-25.
42. Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83: 2906-11.
43. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 1997; 15: 1138-42.
44. Tallman MS, Hakimian D, Rademaker AW, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 1996; 88: 1954-59.
45. Saven A, Burian C, Koziol JA, Piro LD, Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-26.
46. Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998; 16: 3007-15.
47. Robak T, Blasinska-Morawiec M, Krykowski E, et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leukemia Lymphoma 1996; 22: 107-11.
48. Damasio EE, Resegotti L, Masoudi B, et al. Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia. Recenti Prog Med 1998; 89: 68-73.
49. Lauria F, Bocchia M, Marotta G, et al. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia: a new treatment schedule effective and safer in preventing infectious complications. Blood 1997; 89: 1838-39.
50. Chacko J, Murphy C, Duggan C, et al. Weekly intermittent 2-CdA is less toxic and equally efficacious when compared to continuous infusion in hairy cell leukaemia. Br J Haematol 1999; 105: 1145-46.
51. Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995; 13: 989-95.
52. Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996; 14: 2160-66.
53. Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80: 2203-09.
54. Estey EH, Kurzrock R, Kantarjian HM, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992; 79: 882-87.
55. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-48.
56. Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood 1992; 79: 888-94.
57. Carrera C, Piro L, Saven A. Restoration of lymphocyte subsets following 2-chlorodeoxyadenosine remission induction in hairy cell leukemia. Blood 1990; 76 (suppl 1): 260a.
58. Tallman MS, Peterson LC, Hakimian D, et al. Treatment of hairy-cell leukemia: current views. Semin Hematol 1999; 36: 155-63.
59. Dearden CE, Matutes E, Hilditch BL, et al. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol 1999; 106: 515-19.
60. Filleul B, Delannoy A, Ferrant A, et al. A single course of 2-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 1994; 8: 1153-56.
61. Hagberg H. Chimeric monoclonal anti-CD20 antibody (rituximab) - an effective treatment for a patient with relapsing hairy cell leukaemia. Med Oncol 1999; 16: 221-22.
62. Hoffman M, Auerbach L. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. Br J Haematol 2000; 109: 900-01.
63. Zinzani PL, Ascani S, Piccaluga PP, et al. Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol 2000; 18: 3875-77.
64. Lauria F, Lenoci M, Annino L, et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001; 86: 1046-50.
65. Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001; 115: 609-11.
66. Kreitman RJ, Wilson WH, Robbins D, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999; 94: 3340-48.
67. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622-36.
68. Robbins DH, Margulies I, Stetlet-Stevenson M, Kreitman RJ. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of antii-Tac(Fv)-PE38 (LMB-2). Clin Cancer Res 2000; 6: 693-700.
69. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345: 241-47.
70. Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994; 84: 4310-15.
71. Thaler J, Grunewald K, Gattringer C, et al. Long-term follow-up of patients with hairy cell leukaemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration. Br J Haematol 1993; 84: 75-82.
72. Matutes E, Meeus P, McLennan K, Catovsky D. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study. Br J Haematol 1997; 98: 375-83.
73. Wheaton S, Tallman MS, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996; 87: 1556-60.
74. Bastie JN, Cazals-Hatem D, Daniel MT, et al. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leukemia Lymphoma 1999; 35: 555-65.
75. Kampmeier P, Spielberger R, Dickstein J, et al. Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood 1994; 83: 2931-38.
76. Troussard X, Henry-Amar M, Flandrin G. Second cancer risk after interferon therapy? Blood 1994; 84: 3242-44.
77. Kurzrock R, Strom SS, Estey E, et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol 1997; 15: 1803-10.
78. Au WY, Klasa RJ, Gallagher R, et al. Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. Blood 1998; 92: 1160-64.
79. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17: 2454-60.
80. Federico M, Zinzani PL, Frassoldati A, et al. Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol 2002; 20: 638-46.
81. Seymour JF, Estey EH, Keating MJ, Kurzrock R. Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-cholorodeoxyadenosine. Leukemia 1995; 9: 929f-32.